EGFR-TKI 耐药后 MET 扩增检测:从「金标准」到精准优化,破解临床困境


参考文献:
[1]Shun Lu, et al. Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study. 2025 ASCO Abstract # LBA8505.
[2]Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol, 2018, 29(suppl_1): i10-i19.
[3]Matikas A, Mistriotis D, Georgoulias V, et al. Current and future approaches in the management of non-small-cell lung cancer patients with resistance to EGFR TKIs. Clin Lung Cancer, 2015, 16(4): 252-261.
[4]Leonetti A, Sharma S, Minari R , et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer, 2019, 121(9): 725-737.
[5]https://www.hutch-med.com/sachi-phase-iii-trial-initiated/
[6]Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study[J]. Lancet Oncol. 2020 Mar;21(3):373-386.
[7]Wu YL, Cheng Y, Zhou J, et al. Tepotinib plus gefitinib in patients with EGFR‑mutant non‑small‑cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre,randomised trial[J]. Lancet Respir Med, 2020, 8(11):1132-1143.
[8]陈军, 韩宝惠, 胡毅, 等. MET 异常 NSCLC 诊疗专家共识(2025 版). 中国肺癌杂志. 2025, 28(2): 81-93.
[9]Myung-Ju Ahn,et al.SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi.2025 ELCC.2O
[10]Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients[J]. J Clin Oncol, 2009, 27(10): 1667-1674.
[11]中华医学会病理学分会,等. 非小细胞肺癌MET临床检测中国专家共识[J]. 中华病理学杂志, 2022,51(11): 1094-1103.
[12]Imyanitov EN, Preobrazhenskaya EV, Orlov SV. Current status of molecular diagnostics for lung cancer[J]. Explor Target Antitumor Ther. 2024;5(3):742-765.
[13]中国抗癌协会肿瘤病理专业委员会, 等. 非小细胞肺癌融合基因检测临床实践中国专家共识(2023版)[J]. 中华病理学杂志, 2023,52(6) : 565-573.
[14]董晓荣, 柯娥娥. MET 基因检测再精进——评生信优化二代测序识别MET拷贝数变异[J]. 循证医学, 2023; 23(1): 17-20.
[15]S-Y.M. Liu, et al. Optimal Cut-Off with NGS for Metamplification Andclinical Relevance to MET Inhibitor in Non-Small-Cell Lung Cancer. 2024 WCLC P1.06B.14.
[16]Zheng Q, Lin X, Qi W, et al. NGS and FISH for MET amplification detection in EGFR TKl resistant non-small cel lung cancer (NSCLC) patients. A prospective, multicenter study in China[J], Lung Cancer. 2024; 194: 107897.
[17]Hartmaier RJ, Han JY, Byoung Chul Cho, et al. Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small cell lung cancer (NSCLC): biomarker analysis of the TATTON study. AACR 2019. Abstract 4897.
[18]Esagian SM, Grigoriadou GΙ, Nikas IP, et al. Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review[J]. J Cancer Res Clin Oncol. 2020 Aug;146(8):2051-2066.